Were Ross Muken’s SOPHiA GENETICS (SOPH) share sales discretionary?

According to the footnotes, the sales were executed under a pre-established Rule 10b5-1(c) trading plan and “do not represent discretionary trades.” Such plans automate trades according to preset instructions, reducing the timing significance of the transactions.

SOPHiA GENETICS president sells shares for taxes

SOPHiA GENETICS SA President Ross Muken reported two small open-market sales of Ordinary Shares to cover taxes from equity vesting.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

SOPHiA GENETICS SA President Ross Muken reported two small open-market sales of Ordinary Shares to cover taxes from equity vesting. On April 10 and 13, 2026, he sold a total of 8,129 shares at weighted average prices around $4.69–$4.77 per share. A footnote explains these transactions were made to satisfy tax withholding obligations arising from restricted stock units that vested on April 2 and 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. Following the sales, he continues to hold 685,232 Ordinary Shares directly.

Insider Trade Summary 10b5-1

Net Seller: 8,129 shares

Net Sell 2 txns

Insider Muken Ross

Role President

Sold 8,129 shs ($38K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	4,442	$4.765	$21K
Sale	Ordinary Shares	3,687	$4.6864	$17K

Holdings After Transaction: Ordinary Shares — 685,232 shares (Direct)

Footnotes (3)

F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 (c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.61 to $4.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.62 to $4.88, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold total: 8,129 shares April 10 sale size: 3,687 shares April 13 sale size: 4,442 shares +3 more

6 metrics

Shares sold total 8,129 shares Open-market sales on April 10 and 13, 2026

April 10 sale size 3,687 shares Ordinary Shares sold at $4.6864 weighted average

April 13 sale size 4,442 shares Ordinary Shares sold at $4.7650 weighted average

Post-transaction holdings 685,232 shares Ordinary Shares held directly after April 13, 2026 sale

Price range April 10 $4.61–$4.77 Weighted average comprised of multiple trades in that range

Price range April 13 $4.62–$4.88 Weighted average comprised of multiple trades in that range

Key Terms

Rule 10b5-1 (c) trading plan, restricted stock units, weighted average price, open market

4 terms

Rule 10b5-1 (c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1 (c) trading plan adopted by the Reporting Person"

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market financial

"Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SOPHiA GENETICS (SOPH) President Ross Muken report in this Form 4?

He reported selling 8,129 Ordinary Shares in two open-market transactions. These sales were tied to tax withholding obligations from recently vested restricted stock units and were executed under a pre-established Rule 10b5-1(c) trading plan.

How many SOPHiA GENETICS (SOPH) shares did Ross Muken sell and at what prices?

He sold 3,687 Ordinary Shares at a weighted average price of $4.6864 and 4,442 Ordinary Shares at a weighted average price of $4.7650. Footnotes state each sale included multiple trades within narrow price ranges around those averages.

Why did SOPHiA GENETICS (SOPH) President Ross Muken sell shares?

The filing states the sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. This indicates the transactions were compensation-related rather than discretionary open-market selling for portfolio reasons.

How many SOPHiA GENETICS (SOPH) shares does Ross Muken hold after these transactions?

After the April 13, 2026 transaction, he directly holds 685,232 Ordinary Shares. This post-transaction holding figure in the Form 4 shows that, despite the tax-related sales, he retains a substantial equity position in SOPHiA GENETICS.

What does the weighted average price disclosure mean in this SOPHiA GENETICS (SOPH) Form 4?

Weighted average price means each reported price combines several individual trades executed within a stated range. The filing notes prices for the sales ranged roughly from $4.61 to $4.88 and offers to provide full breakdowns upon written request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/14/2026 - 04:02 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muken Ross

(Last)

(First)

(Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON

MASSACHUSETTS

02215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	04/10/2026		S		3,687⁽¹⁾	D	$4.6864⁽²⁾	689,674	D
Ordinary Shares	04/13/2026		S		4,442⁽¹⁾	D	$4.765⁽³⁾	685,232	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 (c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.61 to $4.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.62 to $4.88, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR